Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

ty and efficacy of LX1033 in approximately 360 IBS-d patients. Lexicon also received Fast Track status from the FDA for the development of LX1033 in IBS-d.
  • Other Programs: Lexicon obtained results from Phase 1 studies of  LX2931, an inhibitor of sphingosine-1-phosphate lyase, in patients with rheumatoid arthritis, and LX7101, an inhibitor of LIM domain kinase 2 (LIMK2), in patients with glaucoma.  Both compounds were well-tolerated and showed signals of clinical benefit in the respective studies.
  • Financial ResultsRevenues:  Lexicon's revenues for the three months ended December 31, 2012 decreased 36 percent to $0.2 million from $0.3 million for the corresponding period in 2011. For the year ended December 31, 2012, revenues decreased 41 percent to $1.1 million from $1.8 million for the corresponding period in 2011.

    Research and Development Expenses:  Research and development expenses for the three months ended December 31, 2012 decreased 25 percent to $21.0 million from $28.1 million for the corresponding period in 2011, primarily due to a decrease in external manufacturing, clinical research and development costs. For the year ended December 31, 2012, research and development expenses decreased 10 percent to $82.6 million from $91.8 million for the corresponding period in 2011.

    Increase (Decrease) in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments. Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations. For the three months ended December 31, 2012, the fair value of the Symphony Icon purchase liability decreased by $0.2 million, compared to an increase of $1.6 million in the corresponding period in 2011. For
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon To Present At The BIO CEO & Investor Conference
    2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    4. Lexicon to Provide Third Quarter 2012 Financial Results
    5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    9. Lexicon to Provide Second Quarter 2012 Financial Results
    10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... by IQ4I Research and Consultancy focusing on the active ... about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Ingredients Global Market – Forecast to 2020 ...
    (Date:11/26/2014)... Reinforcing its commitment to enabling confident diagnosis ... PHG AEX: PHIA) today announced 510(k) clearance from ... IQon Spectral CT , presenting an entirely new ... a new dimension to Computed Tomography (CT) imaging, delivering ... based on their material content within a single scan. ...
    (Date:11/26/2014)... Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ASX: ... delivery systems, today announced that its Chairman and CEO, ... the Piper Jaffray 26th Annual Healthcare Conference at the ... Tuesday, December 2, 2014. The conference ... "live" listen only Webcast. To listen, please go to: ...
    Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
    ... 11, 2010 Omthera Pharmaceuticals, Inc., a privately-held ... Wisler, President and Chief Executive Officer, will present ... Conference at the St. Regis hotel in New ... Eastern time. About Omthera ...
    ... 11, 2010 Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ... offering of 11,500,000 shares of its common stock at a ... proceeds from the sale of the shares, after estimated underwriting ... be approximately $86.2 million.  The offering is expected to close ...
    Cached Medicine Technology:Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3
    (Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 (HealthDay ... second language, new research suggests. But anyone who tries to ... boost, the small study finds. The brain "becomes ... Li, co-director of the Center for Brain, Behavior and Cognition ... said, that "the brain networks of the more successful learners ...
    (Date:11/27/2014)... New York, NY (PRWEB) November 27, 2014 ... devoted to offering stylish, comfortable and high functioning compression socks, ... line. The newly-released socks use an innovative Gradient Pressure (TM) ... freshly oxygenated blood. , VIM & VIGR’s commitment to adding ... thought of as just functional recently caught the eye of ...
    (Date:11/27/2014)... VogueQueen.com is making every effort to offer ... world. As the premier online supplier of elegant special ... release a huge selection of sexy prom dresses today. ... also providing many beautiful styles in its product line. ... discounted prices. , “VogueQueen.com hopes to provide a truly ...
    (Date:11/27/2014)... Texas (PRWEB) November 27, 2014 ... report on Global Insulin industry. For an overview ... definition, classification, application, industry chain structure, industry overview, ... on global Insulin industry covers information on ... process, product cost structure and much more. ...
    (Date:11/27/2014)... "The uglier, the better," says Dr. Kirk ... full of laughter as we enjoy the ugly sweater contest." ... sweater from scratch. " It was a sight to see. ... weren't ridiculous enough, the Christmas balls were faces of the ... interested in participating this year, it's simple to get in ...
    Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3
    ... treatment for type 1 diabetes in future, , MONDAY, Aug. ... with type 1 diabetes, researchers were able to produce cells ... though not as efficiently as normal insulin-producing cells do. , ... now have a preliminary lab model of human type 1 ...
    ... BOSTON -- Appropriately selected prostate cancer patients, including ... defer treatment for many years with no adverse consequences, according ... Oncology (JCO). Led by researchers at Beth Israel Deaconess ... the advent of PSA [prostate antigen] screening nearly 20 years ...
    ... Blue ... , ... The emergence of the new H1N1 (swine) flu puts increased emphasis on preparing early for the ... urged to get their flu shot as soon as possible. Since both the seasonal flu and ...
    ... , Safety tips also offered as fires threaten ... American Red Cross is on the scene offering evacuees a safe place ... scorch thousands of acres. Overnight, nearly 200 people took refuge from the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ) , , "If ...
    ... , SANTA CLARA, Calif., Aug. ... September, medical students begin searching for residency training programs. ... students have fewer dollars available to visit multiple residency programs. ... technology, is responding to this need by hosting both an ...
    ... COCONUT CREEK, Fla., Aug. 31 e-Telmed, Inc., ... solution provider and Synergistic Healthcare, a national leader in distributing ... announced today that they have signed an exclusive agreement. This ... the delivery of healthcare in the U.S., it creates a ...
    Cached Medicine News:Health News:Researchers Make Insulin-Producing Cells From Adult Skin Cells 2Health News:Researchers Make Insulin-Producing Cells From Adult Skin Cells 3Health News:'Watchful waiting' is a viable option for prostate cancer patients with low-risk tumors 2Health News:'Watchful waiting' is a viable option for prostate cancer patients with low-risk tumors 3Health News:Flu Season Preparation Comes Early 2Health News:Flu Season Preparation Comes Early 3Health News:Flu Season Preparation Comes Early 4Health News:Red Cross Shelters Wildfire Evacuees 2Health News:Red Cross Shelters Wildfire Evacuees 3Health News:Kaiser Permanente Residency Program Open House 2Health News:e-Telmed, Inc., the Leading Telehealth Solution Provider, Signs Exclusive Agreement with Synergistic Healthcare 2
    Coronary angiographic catheter...
    Leksell Neuro Generator is a complete system for stereotactic lesioning, pain treatment, stimulation and bipolar coagulation. It features a radio frequency (RF) energy source with sophisticated, inte...
    ... a complete offering of cardiology catheters. Available ... catheters are designed with excellent torque, new ... better push-ability, and large inner lumens for ... 6 and 7 French sizes with pressure ...
    The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
    Medicine Products: